Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA.
2006.
An adenoviral vector for probing promoter activity in primary immune cells.. J Immunol Methods. 311(1-2):19-30.
Tripathi P, Madan R, Chougnet C, Divanovic S, Ma X, Wahl LM, Gajewski T, Karp CL, Hildeman DA.
2006.
An adenoviral vector for probing promoter activity in primary immune cells.. J Immunol Methods. 311(1-2):19-30.
Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al..
2009.
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.
Ingallinella P, Bianchi E, Ladwa NA, Wang Y-J, Hrin R, Veneziano M, Bonelli F, Ketas TJ, Moore JP, Miller MD et al..
2009.
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.. Proc Natl Acad Sci U S A. 106(14):5801-6.
Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE et al..
2020.
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).. J Biol Chem. 295(13):4350-4358.
Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE et al..
2020.
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).. J Biol Chem. 295(13):4350-4358.
Weskamp G, Tüshaus J, Li D, Feederle R, Maretzky T, Swendemann S, Falck-Pedersen E, McIlwain DR, Mak TW, Salmon JE et al..
2020.
ADAM17 stabilizes its interacting partner inactive Rhomboid 2 (iRhom2) but not inactive Rhomboid 1 (iRhom1).. J Biol Chem. 295(13):4350-4358.